=Inovio Pharma (INO) : positive HIV vaccine results

Inovio Pharma announces that its HIV vaccine, PENNVAX-GP, maintained durable and robust immune responses at month 12, a full six months after the last dose in a Phase 1 clinical study(4.73 )

More comprehensive immune analyses demonstrated that PENNVAX-GP (plus IL-12) generated HIV-specific CD4+ T cell and binding antibody response rates close to 100% when delivered with either CELLECTRA intramuscular or intradermal devices.

• For instance, 96% (26 of 27) of participants receiving PENNVAX-GP and IL-12 via the IM route demonstrated a CD4+ T cell response while the same percentage (96% or 27 of 28) of participants receiving the vaccine formulation via ID administration also displayed anti-HIV CD4+ T cell responses -- even though those vaccinated via intradermal administration received 1/5th the total dose compared to those vaccinated via the intramuscular device.
• The new data from subjects followed for a full one year of the study showed that the immune responses were maintained in most subjects at month 12 (or six months after the last dose) as evidenced by the durability of activated T cells as well as the magnitude of responder rates. Notably, the percentage of patients who had CD8+ T cell responses immediately after the last dose stayed the same or even increased slightly over the 6 month follow up period, clearly demonstrating durable vaccine-generated memory responses.